Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Divestments (2016 - 2017)

Lisata Therapeutics (LSTA) has disclosed Divestments for 4 consecutive years, with -$74.9 million as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Divestments fell 4179.19% year-over-year to -$74.9 million, compared with a TTM value of -$74.9 million through Sep 2018, down 202.66%, and an annual FY2017 reading of -$189000.0, up 89.2% over the prior year.
  • Divestments was -$74.9 million for Q4 2017 at Lisata Therapeutics, down from $74.9 million in the prior quarter.
  • Across five years, Divestments topped out at $74.9 million in Q3 2017 and bottomed at -$74.9 million in Q4 2017.